TGFB1 and neoplasm: Furthermore IL-7 can enhance anti-tumor immunity by antagonizing inhibitory networks: favoring Th17 differentiation, downregulating transforming growth factor (TGF)-β production, limiting TGF-β-associated signaling, and rendering the effector cells refractory to Treg cells[21], [35], [36], [37].